Dr. Sharif Khan, MD
Claim this profileSaint Francis Hospital / Bon Secours - South Carolina
Studies Myelodysplastic Syndrome
Studies Acute Myeloid Leukemia
4 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Sharif Khan, MD is currently running
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
GFH009
for Blood Cancer
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3.
Recruiting1 award Phase 1 & 27 criteria
More about Sharif Khan, MD
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sharif Khan, MD has experience with
- SEA-CD70
- Ibrutinib
- Autologous Hematopoietic Stem Cell Transplantation
- Autologous Bone Marrow Transplantation
- Lenalidomide
- Daratumumab/rHuPH20
Breakdown of trials Sharif Khan, MD has run
Myelodysplastic Syndrome
Acute Myeloid Leukemia
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sharif Khan, MD specialize in?
Sharif Khan, MD focuses on Myelodysplastic Syndrome and Acute Myeloid Leukemia. In particular, much of their work with Myelodysplastic Syndrome has involved treating patients, or patients who are undergoing treatment.
Is Sharif Khan, MD currently recruiting for clinical trials?
Yes, Sharif Khan, MD is currently recruiting for 3 clinical trials in Greenville South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Sharif Khan, MD has studied deeply?
Yes, Sharif Khan, MD has studied treatments such as SEA-CD70, Ibrutinib, Autologous Hematopoietic Stem Cell Transplantation.
What is the best way to schedule an appointment with Sharif Khan, MD?
Apply for one of the trials that Sharif Khan, MD is conducting.
What is the office address of Sharif Khan, MD?
The office of Sharif Khan, MD is located at: Saint Francis Hospital / Bon Secours - South Carolina, Greenville, South Carolina 29607 United States. This is the address for their practice at the Saint Francis Hospital / Bon Secours - South Carolina.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.